<DOC>
	<DOC>NCT00305630</DOC>
	<brief_summary>Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection with 40 mg of triamcinolone acetonide or observation just prior to PDT. Patients are followed for 6 months. Primary outcome is leakage from choroidal neovascularization (CNV) at 3 months on fluorescein angiography.</brief_summary>
	<brief_title>Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Active choroidal neovascularization Age related macular degeneration Visual acuity 20/20 to 20/400 Neovascular lesion &gt;6500 microns is greatest linear diameter More than one prior photodynamic therapy treatment Receiving systemic corticosteroids Intraocular pressure &gt; 21 mm Hg or glaucoma medication use History of glaucoma or history of ocular hypertension</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Corticosteroids</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Photodynamic therapy</keyword>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Age-related macular degeneration</keyword>
</DOC>